Fatigue Workup in Childbearing Women: Not a Fishing Trip

Four tests. That’s the starting line: CBC, ferritin, TSH, pregnancy test. Not a 30-tube rainbow draw.

“I'm just so tired all the time.” It's one of the most common complaints in primary care, and in women of childbearing age, the differential is simultaneously broad and predictable. The temptation is to order everything—a CMP, CBC, iron studies, B12, folate, vitamin D, cortisol, ANA, Lyme, EBV, celiac panel, ferritin, TSH, free T4, testosterone—and hope something lights up. That's not a workup. That's a fishing trip. And fishing trips catch incidental abnormalities that generate more tests, more anxiety, and no answers.

This post makes the case for a disciplined, stepwise approach.

The Core Four: Start Here, Every Time

The First-Line Panel

1. CBC: Anemia is the most common lab-identifiable cause of fatigue in this population. Look at hemoglobin AND MCV (microcytic = iron deficiency until proven otherwise).
2. Ferritin: Iron deficiency causes fatigue before anemia develops. A normal hemoglobin does NOT rule out iron deficiency. Ferritin is the test that catches the pre-anemic state.
3. TSH: Hypothyroidism is common in women of reproductive age. One test, high yield.
4. Pregnancy test (urine hCG): Fatigue is often the first symptom of early pregnancy, before a missed period is noticed. In any woman of childbearing age with new-onset fatigue, rule it out. It changes everything about your workup and management.

These four tests cover the most common and most treatable causes of fatigue in this population. If all four are normal, then you expand.

Iron Deficiency Without Anemia: The Under-Recognized Entity

This is the clinical pearl that separates a good fatigue workup from a mediocre one. Iron deficiency exists on a spectrum:

• Stage 1: Depleted iron stores (low ferritin, normal hemoglobin, normal MCV). The patient is symptomatic—fatigued, brain fog, exercise intolerance, restless legs—but the CBC is “normal.”
• Stage 2: Iron-deficient erythropoiesis (low ferritin, low transferrin saturation, normal or borderline hemoglobin, possibly low MCV)
• Stage 3: Iron deficiency anemia (low ferritin, low hemoglobin, low MCV, microcytic hypochromic RBCs on smear)

If you only check a CBC and the hemoglobin is 12.5, you'll call it normal and send the patient home. But her ferritin might be 8. She has iron deficiency without anemia—and she'll feel dramatically better with iron replacement.

The Ferritin Threshold Debate

What ferritin level defines iron deficiency? This is more contentious than it should be.

• WHO/traditional cutoff: Ferritin <15 ng/mL = iron deficiency
• Most hematologists and current evidence: Ferritin <30 ng/mL = iron deficiency in the context of symptoms
• Functional iron deficiency (especially with inflammation): Ferritin <100 ng/mL with transferrin saturation <20% may indicate iron deficiency despite “normal” ferritin (ferritin is an acute phase reactant)

For a symptomatic woman of childbearing age, ferritin <30 should be treated as iron deficiency. Multiple RCTs have demonstrated symptom improvement with iron supplementation in non-anemic women with ferritin <50, particularly for fatigue and cognitive function.

When the Core Four Are Normal: Expanding the Workup

Tier 2 (If Core Four Are Normal and Fatigue Persists >4 Weeks)

• BMP: Electrolyte abnormalities (hyponatremia, hypercalcemia), renal insufficiency, glucose (diabetes or hypoglycemia)
• Vitamin D: Deficiency is endemic but its role in fatigue is debated. Check it, but manage expectations—correcting vitamin D may or may not resolve fatigue.
• Depression screening (PHQ-9): This should arguably be Tier 1. Depression and fatigue are intimately linked, and no lab test diagnoses depression. If the PHQ-9 is positive, treat the depression.
• Sleep history: Obstructive sleep apnea is underdiagnosed in women. Ask about snoring, witnessed apneas, morning headaches. STOP-BANG questionnaire.

Tier 3 (If Tier 2 Normal and Specific Symptoms Suggest)

• Celiac panel (tTG-IgA + total IgA): If GI symptoms, iron-refractory iron deficiency, or family history
• ANA: Only if joint pain, rash, photosensitivity, or other autoimmune features are present. Do NOT order ANA as a fishing expedition—the false positive rate in young women is high, and it generates referrals and anxiety without answers.
• Cortisol (AM): Only if Addisonian features (orthostasis, hyperpigmentation, salt craving, weight loss)
• EBV panel: Only if acute-onset fatigue with pharyngitis, lymphadenopathy, splenomegaly. Chronic EBV is not a validated diagnosis; don't order it for chronic fatigue.
• B12/MMA: Lower yield in this population (more relevant for elderly, vegans, post-bariatric surgery)

What NOT to Order (and Why)

Choosing Wisely for Fatigue

• Lyme titers in non-endemic areas: False positives abound. Only test if exposure history + clinical features support it.
• EBV titers for chronic fatigue: Most adults are EBV seropositive. A positive IgG means past exposure, not active disease. It doesn't explain chronic fatigue.
• ANA without autoimmune features: Up to 20% of healthy young women have low-titer positive ANA. A positive ANA without clinical findings generates rheumatology referrals that end with “no autoimmune disease.”
• Morning cortisol without Addisonian features: Random cortisol testing for fatigue has extremely poor specificity. Adrenal insufficiency is rare; poor sleep, depression, and iron deficiency are common.
• Testosterone levels in premenopausal women: Not validated as a fatigue workup tool in this population.
• “Adrenal fatigue” panels: This is not a recognized medical diagnosis. Salivary cortisol panels marketed for “adrenal fatigue” are not evidence-based.

When Labs Are Normal: What Then?

If the Core Four are normal, depression is screened for, sleep is addressed, and Tier 2 labs are unrevealing, the most common diagnoses remaining are:

• Depression/anxiety (may need formal psychiatric evaluation if PHQ-9 doesn't capture it)
• Sleep deprivation (the most undertreated cause of fatigue in working mothers)
• Obstructive sleep apnea (consider sleep study)
• Chronic fatigue syndrome / ME/CFS: Diagnosis of exclusion. Requires ≥6 months of unexplained fatigue + post-exertional malaise + unrefreshing sleep. Validate the patient's experience.
• Lifestyle factors: Overcommitment, caregiving burden, inadequate nutrition, deconditioning

The most important thing at this stage is to believe the patient. “Your labs are normal” doesn't mean “you're fine.” It means the labs didn't find the answer. The fatigue is real.

Iron Replacement: Practical Notes

• Oral iron: Ferrous sulfate 325 mg (65 mg elemental iron) every other day is better absorbed than daily (hepcidin rebound with daily dosing). Take with vitamin C, empty stomach, avoid calcium/coffee/tea within 2 hours.
• IV iron: Consider for ferritin <15 with Hgb <10, oral intolerance, malabsorption (celiac, IBD, bariatric surgery), second/third trimester pregnancy with significant anemia, or failure to respond to 4–6 weeks of oral iron.
• Recheck ferritin at 8–12 weeks. Goal: ferritin >50 (some argue >100 for sustained repletion).
• Identify the source: Heavy menstrual bleeding is the most common cause of iron deficiency in this population. Screen with pictorial bleeding assessment chart (PBAC) or menstrual history. If HMB is present, treat the bleeding (hormonal management, referral to GYN) in addition to replacing iron.

Bottom Line

Fatigue in childbearing women is best approached with discipline, not a shotgun. Start with CBC, ferritin, TSH, and a pregnancy test. Ferritin <30 in a symptomatic woman is iron deficiency regardless of hemoglobin. If the Core Four are normal, screen for depression and sleep disorders before adding labs. Don't order ANA, EBV, or cortisol without specific clinical indications. And when all the labs come back normal, the fatigue is still real—acknowledge it, investigate further, and keep advocating for your patient.

Stay sharp out there.

 

Pap Smear Interpretation: Bethesda Classification, HPV Co-Testing, and the ASCCP Management Guidelines

ASC-US with negative HPV? Routine screening. AGC? Colposcopy, endocervical curettage, and possibly endometrial biopsy. Know the difference.

Cervical cancer screening has evolved dramatically, yet the interpretation of results and management algorithms remain a source of confusion for many providers. The shift from cytology-only screening to HPV co-testing and primary HPV screening has changed when and how we act on results. This post walks through the Bethesda classification system, the current screening strategies, and the 2019 ASCCP risk-based management consensus guidelines.

Current Screening Strategies

Age Group	Preferred Strategy	Acceptable Alternatives	Interval
<21 years	No screening (regardless of sexual activity or HPV vaccination status)	None	N/A
21–24 years	Cytology (Pap) alone	No HPV testing in this age group (too many transient infections)	Every 3 years
25–65 years	Primary HPV testing alone (FDA-approved tests) every 5 years	HPV + cytology co-testing every 5 years, OR cytology alone every 3 years	See strategy
>65 years	Discontinue if adequate prior screening and no history of CIN2+	Adequate = 3 consecutive negative cytology or 2 consecutive negative co-tests in prior 10 years, most recent within 5 years	N/A
Post-hysterectomy (total, with cervix removed)	No screening if no history of CIN2+ and the hysterectomy was for benign indications	Continue screening if history of CIN2+ (screen for 25 years after treatment)	N/A

The Primary HPV Shift

The ACS (2020) and USPSTF (2018) now endorse primary HPV testing as the preferred strategy for ages 25–65. This means HPV testing alone—without concurrent cytology—as the first-line screen. If the HPV test is positive, reflex cytology (triage Pap) is performed on the same specimen. This approach has higher sensitivity for CIN3+ than cytology alone. The key HPV genotypes to know: HPV 16 and HPV 18 are highest risk and warrant direct colposcopy referral even with normal cytology.

The Bethesda Classification System

Result	Full Name	What It Means	Management Summary
NILM	Negative for Intraepithelial Lesion or Malignancy	Normal. May note benign findings (inflammation, atrophy, reactive changes).	Return to routine screening per age-appropriate interval.
ASC-US	Atypical Squamous Cells of Undetermined Significance	Mildly abnormal cells that could be reactive or low-grade. Most common abnormal result.	Reflex HPV testing. If HPV(+): colposcopy. If HPV(−): return in 3 years (co-test) or 5 years (primary HPV).
ASC-H	Atypical Squamous Cells, cannot exclude HSIL	More concerning than ASC-US; higher likelihood of underlying CIN2/3.	Colposcopy regardless of HPV status.
LSIL	Low-grade Squamous Intraepithelial Lesion	Equivalent to CIN1/HPV effect. Most regress spontaneously, especially in young women.	Ages 21–24: repeat cytology in 1 year. Ages ≥25: colposcopy (per ASCCP guidelines, management mirrors ASC-US HPV+).
HSIL	High-grade Squamous Intraepithelial Lesion	Equivalent to CIN2/3. Significant precancer risk.	Expedited treatment (LEEP) or colposcopy depending on age and risk factors. Non-pregnant, ≥25, not concerned about fertility: immediate LEEP is acceptable.
AGC	Atypical Glandular Cells	Abnormal glandular cells. Can originate from endocervix OR endometrium. Higher risk of significant pathology than ASC-US.	Colposcopy + endocervical curettage (ECC) for ALL. Add endometrial biopsy if ≥35 years, abnormal uterine bleeding at any age, or AGC “favor neoplasia.”
AIS	Adenocarcinoma In Situ	Glandular precancer of the endocervix.	Colposcopy + ECC + diagnostic excision. Hysterectomy is the definitive treatment for completed childbearing.
SCC / Adenocarcinoma	Squamous Cell Carcinoma / Adenocarcinoma	Invasive cancer on cytology.	Urgent referral to gynecologic oncology.

AGC Is Never Routine

AGC (Atypical Glandular Cells) is the result that demands the most aggressive workup relative to how benign it sounds. Unlike ASC-US, which is usually nothing, AGC carries a 9–38% risk of significant pathology (CIN2+, AIS, or endometrial pathology). Every AGC result requires colposcopy with endocervical curettage. In women ≥35 or with abnormal uterine bleeding, add endometrial biopsy. AGC “favor neoplasia” carries the highest risk and may require diagnostic excisional procedure even if colposcopy is negative.

The ASC-US Reflex Algorithm

ASC-US is the most common abnormal Pap result and accounts for the majority of follow-up decisions in primary care. The reflex HPV test (run on the same specimen) is the triage tool:

• ASC-US + HPV negative: Return to routine screening (every 3 years with co-testing, or every 5 years with primary HPV). The negative HPV essentially rules out significant disease.
• ASC-US + HPV positive (not 16/18): Repeat co-testing in 1 year. If persistent ASC-US/HPV+ or worse, colposcopy.
• ASC-US + HPV 16 or HPV 18 positive: Proceed directly to colposcopy. HPV 16/18 carry the highest CIN3+ risk.

The 2019 ASCCP Risk-Based Management Guidelines

The Paradigm Shift

The 2019 ASCCP guidelines moved from result-based management (same result = same action) to risk-based management (same result + different history = different action). The key principle: management is determined by the patient's estimated risk of CIN3+ based on current results AND prior screening history. Two patients with LSIL may be managed differently if one has a history of normal screens (lower risk) and the other has prior ASC-US (higher risk). Use the ASCCP management guidelines app or risk tables at asccp.org.

Special Populations

Ages 21–24

HPV is extremely common and usually transient in this age group. Management is more conservative: ASC-US and LSIL are managed with repeat cytology in 1 year, not immediate colposcopy. HSIL still warrants colposcopy. No HPV co-testing (high false positive rate from transient infections).

Pregnancy

Colposcopy can be performed during pregnancy (no endocervical curettage). Treatment (LEEP, excision) is deferred until postpartum unless invasive cancer is suspected. Cervical biopsy is acceptable during pregnancy if indicated by colposcopic findings.

Immunocompromised (HIV+)

Start screening at age 21 (within 1 year of sexual debut for HIV+). Screen annually with cytology (21–29) or co-testing (30+). After 3 consecutive normal results, can extend to every 3 years. Never stop screening (no age cutoff). HPV persistence and progression are more common.

Post-HPV Vaccination

Vaccinated individuals follow the same screening guidelines as unvaccinated. The vaccine doesn't cover all high-risk HPV types, and patients may have been exposed before vaccination. Screening intervals and management don't change.

The Pitfalls

• Don't Pap women under 21: No exceptions. Even with sexual activity, HPV exposure, or abnormal symptoms. If symptomatic, evaluate the symptoms—don't screen for cervical cancer.
• Don't HPV-test women 21–24: Transient HPV is ubiquitous in this age group. A positive HPV in a 22-year-old causes anxiety and overtesting with no benefit.
• AGC is not ASC-US: The workup is fundamentally different. AGC always needs colposcopy + ECC. Don't just repeat the Pap.
• Post-hysterectomy screening errors: If the cervix was removed for benign indications and there's no CIN2+ history, screening is over. If the cervix was NOT removed (supracervical hysterectomy), screening continues.
• Don't over-screen: Co-testing every year is not indicated for normal-risk patients. It leads to false positives and unnecessary colposcopies. Stick to the recommended intervals.
• Inadequate specimen: An “unsatisfactory” Pap needs to be repeated in 2–4 months, not in a year. Don't let it fall through the cracks.

Bottom Line

Cervical cancer screening saves lives when done correctly—at the right intervals, with the right tests, and with appropriate follow-up. Primary HPV testing is the preferred strategy for 25–65. ASC-US with negative HPV is reassuring. AGC is never reassuring. HPV 16/18 positivity warrants colposcopy regardless of cytology. And the 2019 ASCCP guidelines mean that a patient's screening history now drives management, not just the current result. Use the ASCCP risk tables and manage accordingly.

Stay sharp out there.

Polypharmacy Lab Monitoring: The Drug-Induced Lab Derangements You’re Missing

 

Polypharmacy Lab Monitoring: The Drug-Induced Lab Derangements You’re Missing

The triple whammy. Euglycemic DKA. PPI-induced hypomagnesemia. These aren’t zebras—they’re happening in your panel right now.

The average adult over 65 takes 5+ medications. Each one has lab consequences. The problem isn't that we don't know these interactions exist—it's that we forget to monitor for them, especially when multiple medications interact to create compounding effects that no single drug would produce alone. This post catalogs the drug-lab interactions that primary care NPs encounter most often and the monitoring schedules that prevent them from becoming emergencies.

The Dangerous Combinations

The Triple Whammy: ACEi/ARB + NSAID + Diuretic

High-Alert Combination

An ACE inhibitor or ARB dilates the efferent arteriole. An NSAID constricts the afferent arteriole. A diuretic reduces intravascular volume. Together, all three mechanisms converge on the kidney to create a perfect storm of acute kidney injury. This combination is one of the most common causes of preventable AKI in the elderly. Monitor BMP within 1–2 weeks of adding any of these three to a patient already on one of the others. The holiday weekend AKI—patient starts an OTC NSAID for back pain while on lisinopril and HCTZ—is a classic.

The Lithium + NSAID + ACEi Triad

NSAIDs reduce renal lithium clearance. ACEi/ARBs reduce renal lithium clearance. Together, they can push a stable lithium level into the toxic range (>1.5 mEq/L) within days. Check lithium levels within 5–7 days of adding an NSAID or ACEi to a patient on lithium. Counsel patients to avoid OTC NSAIDs.

Drug-by-Drug Lab Monitoring Guide

Drug/Class	Lab Derangement	What to Monitor	When
SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin)	Euglycemic DKA	BMP (anion gap), urinalysis for ketones. Blood glucose may be NORMAL (<250)—check ketones if acidotic.	Sick days, perioperative period, low-carb diets. Hold 3–4 days before surgery.
PPIs (omeprazole, pantoprazole, etc.)	Hypomagnesemia, B12 deficiency, iron malabsorption, calcium malabsorption (fracture risk)	Magnesium (especially if also on diuretics), B12 annually if chronic use >1 year	Baseline, then annually. Every 6 months if symptomatic or on concurrent loop diuretics.
Metformin	B12 deficiency (10–30% over years), lactic acidosis (rare, with renal impairment)	B12 annually, BMP/eGFR every 6–12 months. Contraindicated if eGFR <30, reduce dose if 30–45.	B12 annually. eGFR at baseline, then 3–6 months, then annually.
DOACs (apixaban, rivarelbán, edoxaban)	Accumulation in renal decline; no routine drug level monitoring available	eGFR. Rivaroxaban: avoid if CrCl <15. Apixaban: dose-reduce if 2 of 3: age ≥80, weight ≤60 kg, Cr ≥1.5.	eGFR every 6 months. More frequently if baseline CKD or acute illness.
Thiazide diuretics	Hyponatremia, hypokalemia, hypercalcemia, hyperuricemia, hyperglycemia	BMP (Na, K, Ca, glucose, BUN/Cr), uric acid if gout history	1–2 weeks after initiation, then every 6–12 months.
Loop diuretics (furosemide, bumetanide)	Hypokalemia, hypomagnesemia, hypocalcemia, hyponatremia, metabolic alkalosis	BMP + magnesium	1–2 weeks after dose change, then every 3–6 months.
Spironolactone / eplerenone	Hyperkalemia (especially with ACEi/ARB + CKD)	Potassium + BMP	Within 1 week, then 1 month, then every 3 months. Increase frequency if eGFR declining.
Statins	Elevated transaminases, CK elevation / rhabdomyolysis (rare)	LFTs at baseline. CK only if symptomatic (myalgia).	No routine monitoring needed per guidelines. Check LFTs/CK only if symptomatic.
Amiodarone	Thyroid dysfunction (both hypo- and hyper-), hepatotoxicity, pulmonary toxicity	TFTs (TSH, free T4) every 6 months, LFTs every 6 months, PFTs annually, CXR annually	Baseline + every 6 months for TFTs/LFTs. Continue monitoring for 12+ months after discontinuation (long half-life).
Carbamazepine / oxcarbazepine	Hyponatremia (SIADH), leukopenia, hepatotoxicity	Sodium, CBC, LFTs, drug level	Baseline, 2 weeks, 1 month, then every 3–6 months.
Valproic acid	Hepatotoxicity, thrombocytopenia, hyperammonemia, pancreatitis	LFTs, CBC, ammonia level (if encephalopathy), lipase if abdominal pain, drug level	Baseline, 1 month, then every 6 months.

Euglycemic DKA: The SGLT2 Trap

High-Yield Clinical Pearl

SGLT2 inhibitors cause glycosuria, which lowers blood glucose but can promote ketogenesis in certain conditions: illness, fasting, low-carb/keto diets, surgery, alcohol use. The result is DKA with a blood glucose that may be <250 mg/dL—sometimes even <200. This is euglycemic DKA, and it's missed because everyone expects DKA to present with glucose >300. If a patient on an SGLT2i presents with nausea, vomiting, abdominal pain, tachypnea, or malaise, check an anion gap and serum/urine ketones regardless of glucose.

Sick-day rules: Instruct patients to hold their SGLT2i during any acute illness, fasting, or perioperative period. Hold 3–4 days before elective surgery.

PPI-Induced Hypomagnesemia: The Silent Cascade

Chronic PPI use (>3–6 months) reduces intestinal magnesium absorption. Hypomagnesemia then causes:

• Refractory hypokalemia: Magnesium is required for the Na-K-ATPase pump. You cannot correct potassium until magnesium is repleted.
• Refractory hypocalcemia: Magnesium is required for PTH secretion and action.
• QT prolongation: Especially dangerous if the patient is also on QT-prolonging medications (fluoroquinolones, antipsychotics, ondansetron).

This cascade explains the patient who keeps coming in with hypokalemia despite potassium supplementation. Check the magnesium—it's the upstream problem.

The DOAC + Declining Renal Function Problem

Monitoring Gap

DOACs don't require routine coagulation monitoring, which is their advantage. But they DO require regular renal function monitoring because all DOACs have some renal clearance. Rivaroxaban and edoxaban are most affected; apixaban is least. An elderly patient started on a DOAC at age 75 with a CrCl of 60 may have a CrCl of 35 by age 80. That's the difference between standard dosing and dose reduction (or contraindication). Check eGFR every 6 months in elderly DOAC patients, more often with CKD or intercurrent illness.

Monitoring Schedules by Visit Type

At Every Chronic Disease Visit

• Review medication list for high-risk combinations
• Ask about OTC NSAIDs, supplements, herbal products
• Check orthostatics if on antihypertensives + diuretics

Annually

• BMP (for diuretics, ACEi/ARB, SGLT2i, metformin)
• B12 (for metformin, chronic PPI)
• Magnesium (for chronic PPI, especially if on concurrent diuretics)
• TSH (for amiodarone, lithium)

After Any Medication Change

• BMP at 1–2 weeks for new diuretic, ACEi/ARB, or spironolactone
• Drug level at steady state for new lithium, carbamazepine, valproic acid, digoxin
• CBC at 4–6 weeks for new carbamazepine, valproic acid, or methotrexate

The Pitfalls

• OTC NSAIDs are invisible: Patients don't consider them “medications.” Always ask specifically about ibuprofen, naproxen, and aspirin.
• Herb-drug interactions: St. John's Wort decreases levels of warfarin, DOACs, statins, digoxin, and many others via CYP3A4 induction. Ask about supplements.
• The statin CK myth: Routine CK monitoring in asymptomatic statin patients is not recommended. Check only for myalgia symptoms.
• “Stable” medications still need monitoring: A patient on the same lisinopril dose for 10 years still needs periodic BMP—their kidneys at 85 aren't what they were at 75.
• Sick-day rules save lives: Instruct elderly patients to hold metformin, SGLT2i, diuretics, and ACEi/ARB during acute illness with decreased oral intake. Provide written sick-day cards.

Bottom Line

Polypharmacy creates lab derangements that are predictable and preventable—if you're monitoring for them. The triple whammy causes AKI. SGLT2i cause euglycemic DKA. PPIs cause a magnesium deficit that cascades into hypokalemia and hypocalcemia. DOACs accumulate as kidneys decline. Build the monitoring into your workflow: check the BMP after every medication change, check the magnesium on every patient on a PPI + diuretic, and teach your patients sick-day rules before they need them.

Stay sharp out there.

 

Age-Adjusted Lab Norms: Why Adult Reference Ranges Lie About Children and the Elderly

A creatinine of 1.0 is normal in a 30-year-old. It’s kidney failure in a 5-year-old and possibly masked disease in a sarcopenic 85-year-old.

Lab reference ranges printed on a report were derived from adult populations. They don't account for the physiology of a growing child or an aging body losing muscle mass. Applying adult normals to pediatric or geriatric patients leads to missed diagnoses, unnecessary workups, and false reassurance. This post covers the labs that change most dramatically by age and the clinical traps they create.

The Big Offenders: Labs Where Age Changes Everything

Lab	Pediatric Shift	Geriatric Shift	Clinical Trap
Creatinine	Much lower in children (0.2–0.4 in infants, 0.3–0.7 in school-age). A cr of 1.0 = significant renal impairment in a child.	Decreases with sarcopenia. A “normal” 1.0 may represent GFR of 40 in a frail elderly patient.	Creatinine-based GFR overestimates kidney function in low-muscle-mass patients at both extremes of age.
Alkaline Phosphatase (ALP)	2–3x adult normal during growth spurts (especially puberty). ALP >500 can be normal in a rapidly growing adolescent.	Mildly elevated in osteoporosis, Paget's disease.	Chasing an elevated ALP in a growing child as “liver disease” leads to unnecessary workup. Check GGT—if GGT is normal, the ALP is from bone.
ESR	Very low in neonates (0–2). Gradually rises through childhood.	Rises with age. Adjusted formula: men = age/2; women = (age+10)/2. An ESR of 40 may be “normal” for an 80-year-old.	Using the standard “ESR <20” cutoff in elderly patients labels nearly everyone as abnormal.
TSH	Higher in neonates (up to 10–20 mIU/L in first days of life, normalizes by 1 month).	TSH drifts upward with healthy aging. TSH 5–7 in an 80-year-old may be the new normal, not subclinical hypothyroidism.	Treating mild TSH elevation in the elderly risks atrial fibrillation and osteoporosis from overreplacement. Multiple guidelines now recommend against treating TSH <10 in patients >70–80.
Hemoglobin	Physiologic nadir at 6–9 weeks (Hgb ~9.5 in term infants). Fetal hemoglobin confounds MCV interpretation.	Lower thresholds debated. WHO defines anemia as Hgb <12 (women) and <13 (men), but some argue these are too conservative for elderly, while others argue anemia in the elderly always deserves workup.	Dismissing anemia in the elderly as “normal aging” misses GI malignancy, MDS, and nutritional deficiency.
WBC	Higher in neonates and infants (up to 30K). Lymphocyte predominance from ~4 months to ~4 years (the “lymphocyte crossover”).	May trend lower. Blunted leukocytosis in response to infection is common.	An elderly patient with a WBC of 11K and sepsis has a muted response—don't be reassured by a “normal” WBC.
BUN	Lower in children (5–18 mg/dL typical).	Rises with dehydration, GI bleeding, high protein intake, renal decline. Less reliable as a GFR marker.	Elevated BUN in elderly is multifactorial—don't assume renal failure without checking creatinine and GFR.

Creatinine and GFR: The Sarcopenia Problem

The Dangerous Reassurance

Serum creatinine is a product of muscle metabolism. Less muscle = less creatinine production = lower baseline. A frail 85-year-old woman weighing 45 kg may have a creatinine of 0.8 that looks “normal” on the lab report but represents a GFR of 35 mL/min (Stage 3b CKD). Always calculate eGFR—and consider cystatin C in patients where creatinine-based estimates are unreliable.

When to Use Cystatin C

• Sarcopenic elderly: Low muscle mass makes creatinine unreliable
• Extremes of body composition: Very muscular or very cachectic patients
• Amputees
• Vegetarian/vegan diet: Lower dietary creatine intake
• When creatinine-based eGFR seems inconsistent with clinical picture

Cystatin C is produced by all nucleated cells at a constant rate, independent of muscle mass. The CKD-EPI creatinine-cystatin C combined equation provides the most accurate GFR estimate in these populations.

The Pediatric Lymphocyte Crossover

Pediatric Pearl

From approximately 4 months to 4 years of age, children have a lymphocyte-predominant differential (60–70% lymphocytes). This is normal. A CBC showing 65% lymphocytes in a 2-year-old is physiologic, not leukemia. After age ~4–6, the adult pattern (neutrophil predominance) establishes. Panicking over lymphocyte predominance in a toddler leads to unnecessary hematology referrals.

TSH in the Elderly: The Overtreatment Trap

Multiple large studies (TRUST, IEMO) have demonstrated that treating mild subclinical hypothyroidism (TSH 4.5–10) in adults over 65–70 provides no benefit in symptoms, quality of life, or cardiovascular outcomes. The 2023 ETA guidelines and multiple position statements now recommend:

• For patients >70–80 with TSH 4.5–10: monitor, don't treat unless symptomatic with clearly attributable symptoms
• For patients >80 with TSH up to ~10: Consider this the patient's physiologic setpoint. Treatment risks include atrial fibrillation, osteoporosis, and anxiety.
• Always check anti-TPO before deciding to monitor vs. treat. Positive antibodies increase progression risk.

The Overtesting Problem in Healthy Elderly

Choosing Wisely

A healthy 82-year-old who gets an annual “comprehensive metabolic panel + CBC + everything” will inevitably have abnormalities. With 20 tests, there's a ~64% probability that at least one result falls outside the reference range by chance alone (assuming 95% specificity per test). This triggers a cascade: the abnormal result gets repeated, then a specialist referral, then imaging, then a procedure—all for a statistical artifact. Test with a question in mind, not as a fishing expedition. Ask: “What will I do differently based on this result?” If the answer is nothing, don't order it.

Other Age-Dependent Labs Worth Knowing

• D-dimer: Rises with age. Age-adjusted cutoff (age × 10 μg/L for patients >50) reduces false positives for PE/DVT workup without sacrificing sensitivity.
• PSA: Rises naturally with prostate growth. Age-specific ranges exist but are controversial.
• B12: Declines with age due to decreased absorption (atrophic gastritis, PPI use). Low-normal B12 (200–400 pg/mL) in the elderly deserves MMA/homocysteine confirmation.
• Albumin: Declines slightly with age but also reflects nutrition, inflammation, and liver function. Don't dismiss low albumin as “aging.”
• Testosterone: Declines ~1–2% per year after age 30. Age-adjusted norms should be used.
• Calcium: Adjust for albumin in hypoalbuminemic elderly. Corrected calcium = measured Ca + 0.8 × (4.0 − albumin).

Bottom Line

The number on the lab report means nothing without the patient's age and body composition. A “normal” creatinine hides kidney disease in the sarcopenic elderly. An “elevated” ALP is expected in a growing adolescent. A mildly high TSH in an octogenarian may need watching, not treatment. Every lab result is a data point that requires clinical context—and at the extremes of age, the context changes everything.

Stay sharp out there.